Ganciclovir Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Ganciclovir Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Approved
Highest phase
145
Registered trials
43
Result records
42
Matched deals
Executive recommendation: GO
Decision memo
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
The central underwriting question is whether Ganciclovir can convert its Small molecule drug profile and DNA polymerase biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Ganciclovir (query alias: ganciclovir) |
|---|---|
| Modality / target | Small molecule drug; DNA polymerase; DNA polymerase inhibitors |
| Highest global status | Approved |
| Originator | Syntex Corp. |
| Active developers | Hainan Poly Pharm. Co., Ltd., Bausch & Lomb, Inc., Chong Kun Dang Pharmaceutical Corp. |
The MCP disease footprint includes Keratitis, Herpetic, Cytomegalovirus Retinitis, Cytomegalovirus Infections. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT07450365 | Phase 4 | Not yet recruiting | 150 | Death |
| NCT07513623 | Phase 2 | Not yet recruiting | 117 | Primary Outcome Measure - Trial I |
| ChiCTR2600126010 | Not Applicable | Not yet recruiting | 220 | 6-month all-cause mortality rate |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
Systemic and Topical Antivirals for Control of Cytomegalovirus Anterior Uveitis: Treatment
Phase 2/3; n=51; evaluation: not stated. Reported fields: Change in CMV Viral Load(Mean) = 0.04 log10 IU/mL (Standard Deviation, 0.44); -; -
Ganciclovir to Prevent Reactivation of Cytomegalovirus in Patients With Acute Respiratory Failure and Sepsis
Phase 3; n=205; evaluation: not stated. Reported fields: Respiratory-support-free Days in Immunocompetent Patients With Sepsis-associated Acute Respiratory Failure(Mean) = 14.6 days (Standard Deviation, 10.5); Respiratory-support-free Days in Immunocompetent Patients With Sepsis-associated Acute Respiratory Failure(Mean): P-Value = 0.098; Respiratory-support-free Days in Immunocompetent Patients With Sepsis-associated Acute Respiratory Failure(Mean) = 12.1 days (Standard Deviation, 11.1)
Multimodal Management of Refractory CMV Retinitis in an Immunocompromised Host: Role of Intravitreal Foscarnet, Systemic Antivirals, and Anti-VEGF Therapy.
Not Applicable; n=1; evaluation: Positive. Reported fields: AE = Transient ocular hypertension (IOP: 25 mmHg) post- injection, managed with topical timolol. Cystoid macular edema in OS (GMC: 242 μm) resolved after 3 monthly aflibercept injections.
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Ganciclovir addresses Keratitis, Herpetic, Cytomegalovirus Retinitis, Cytomegalovirus Infections. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 42 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
Transaction-scope note: No direct asset-specific transaction was returned. The table below shows target-level comparable: DNA polymerase records as comparable precedents only.
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2026-04-23 | Dogwood Therapeutics Announces Worldwide Development and Commercialization Partnership for Anti-Viral Assets with Potential Value up to $100M | Discontinued | US$100.0M stated total |
| 2025-12-24 | Repare Therapeutics Announces Acquisition of Polθ ATPase Inhibitor, RP-3467, by Gilead Sciences for Up To $30 Million in Total Consideration | Phase 1 | US$25.0M upfront; US$5.0M milestones; US$30.0M stated total |
| 2025-12-08 | GSK Cuts Five-Year-Old Cancer Collaboration With Ideaya | Preclinical | US$100.0M upfront |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
The milestone feed surfaced a patent-application signal described as “Ganciclovir for injection and preparation method thereof”. The milestone feed surfaced a patent-application signal described as “New application of ganciclovir”. The milestone feed surfaced a patent-application signal described as “Ganciclovir compatible impurity as well as preparation method and application thereof”.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Therapeutic index across KRAS/BRAF mutation subgroups
- On-target toxicity and adaptive MAPK resistance
- Lack of matched efficacy results in the current MCP result set
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
GO
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 15 July 2026. Counts and status fields may change as source records update.
